Stockholm’s BioLamina Raises €20M EIB Loan To Scale Cell Therapy Development

The funding is structured as venture debt, providing long-term capital to help the company scale while limiting dilution for existing shareholders.

Founded in 2009 by Dr Karl Tryggvason and Kristian Tryggvason, BioLamina develops solutions to support scientists working with stem cells and primary cells.

The company produces laminin-based cell culture substrates that enable reliable cell growth and differentiation in laboratory settings. These proteins, based on the founders’ research, help ensure consistent, high-quality cells supporting the development of cell therapies and more accurate drug testing.

Read Also - Flare Raises €3.6M To Build AI-era Knowledge Validation Platform

BioLamina provides high-quality scalable cell culture solutions designed to support researchers in advancing cell therapies and improving drug discovery models. Its laminin based technologies enable precise and reliable cell growth, supporting next generation therapies and animal-free drug testing methods.

The €20 million financing from the European Investment Bank (EIB) will help expand the development and production of these technologies. The funding will support manufacturing scale-up, product portfolio expansion, and overall business growth.

BioLamina’s solutions are used in developing treatments for conditions such as diabetes, Parkinson’s disease, heart failure, liver disease, and cancer many of which remain difficult to treat.

Its Biolaminin® substrates are fully defined, animal-origin-free recombinant proteins used in clinical-stage cell therapy development.

The investment also aligns with broader EU initiatives, including InvestEU, TechEU, and BioTechEU, aimed at strengthening innovation and competitiveness in biotechnology.

“Europe needs to turn scientific excellence into global companies. By supporting BioLamina’s growth, we are helping ensure that cutting-edge innovation in life sciences can scale in Europe, creating jobs, strengthening competitiveness and ultimately improving public health,” said EIB Vice-President Karl Nehammer.

“Cell therapies are rapidly moving from scientific promise to clinical reality, but scaling the production of high-quality cell products remains a fundamental challenge. This financing allows us to expand our technology and manufacturing capabilities at a critical time supporting more reliable and scalable development of next-generation therapies,” said BioLamina CEO Klaus Langhoff-Roos.